Treatment with HMA in MDS results in the upregulation of previously methylated and silenced tumor genes that express antigens such as NY-ESO-1, MAGE-A3, PRAME, and WT1 [133]. The gene discussed is MAGEA3; the disease is myelodysplastic syndrome.